Descripción del proyecto
Nueva plataforma de cultivo celular tridimensional para sustituir a los animales en los ensayos preclínicos
Hoy día, más del 85 % de los ensayos clínicos iniciales fracasan a pesar de los resultados prometedores de las pruebas preclínicas «in vitro». La razón principal de este hecho está asociada con los cultivos celulares bidimensionales «in vitro», que no logran recapitular el entorno del organismo vivo. Por lo tanto, los ensayos preclínicos con animales siguen siendo un punto de referencia, a pesar del coste y los problemas éticos conexos. La empresa checa InoCure está desarrollando una plataforma de matrices tridimensionales única para el cultivo celular «in vitro» con un sistema integrado de administración de fármacos. El objetivo es mejorar de forma notable la eficacia de la aplicación preclínica a la clínica y, al mismo tiempo, ofrecer una alternativa a los ensayos con animales. El equipo del proyecto DifMATRIX, financiado con fondos europeos, se propone realizar el estudio de viabilidad, evaluando la viabilidad jurídica, económica y técnica de la introducción de la tecnología en el mercado.
Objetivo
The use of in-vitro testing (in simulated environment) is the future of drug development, cancer research and medical research in general since it overcomes the practical and ethical issues associated with human and animal experimentation. However, as much as 85% of early clinical trials currently fail despite successful preclinical in-vitro testing; in the case of clinical cancer trials it is less than 8%. The main reason for such low success rates is that currently used 2D cells do not behave the same in living bodies as in cultures. As a consequence, animal testing continues to be widespread despite the associated cost and strong ethical concerns it raises. This is also extremely costly in time and resources which raise consumer prices for life-saving medications.
InoCure is addressing this problem with the DifMATRIX - a unique 3D scaffolding platform with drug delivery embedded system, for cell culture used in molecular biology and tissue engineering. DifMATRIX enables to simulate natural cell phenotype (in vivo) in the in-vitro environment. It redefines in-vitro preclinical testing standards, significantly improving preclinical-to-clinical translation efficiency and provide an alternative to animal testing models. The predicted impact of the project is to eliminate the animal testing phase from the drug development process.
The project is well aligned with new trends in cell and tissue culture supplier market. Globally, this market is witnessing significant growth due to increasing demand for biopharmaceuticals and increasing R&D in this field. The global cell/tissue engineering supplies market is expected to reach $28 billion in 2020. The market demand for DifMATRIX has been confirmed by customers currently using our passive InoMATRIX product, and by the letters of intent from prospective customers.
Following the proposed Phase 1, Inocure target is to apply for the Phase 2 project to scale-up the production and launch commercialisation of DifMATRIX.
Ámbito científico
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesmedical biotechnologytissue engineering
- medical and health sciencesclinical medicineoncology
- natural sciencesbiological sciencesmolecular biology
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEINST-1-2016-2017
Régimen de financiación
SME-1 - SME instrument phase 1Coordinador
11000 Praha
Chequia
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.